Chronic inflammation and mortality in haemodialysis: effect of different renal replacement therapies. Results from the RISCAVID study | Zendy

Vincenzo Panichi | Zendy; Giovanni Manca Rizza | Zendy; Sabrina Paoletti | Zendy; Roberto Bigazzi | Zendy; Marta Aloisi | Zendy; Giovanni Barsotti | Zendy; P Rindi | Zendy; Gabriele Donati | Zendy; Alessandro Antonelli | Zendy; Erica Panicucci | Zendy; Giovanni Tripepi | Zendy; Ciro Tetta | Zendy; Roberto Palla | Zendy

Open Access

Chronic inflammation and mortality in haemodialysis: effect of different renal replacement therapies. Results from the RISCAVID study

Author(s) -

Vincenzo Panichi,

Giovanni Manca Rizza,

Sabrina Paoletti,

Roberto Bigazzi,

Marta Aloisi,

Giovanni Barsotti,

P Rindi,

Gabriele Donati,

Alessandro Antonelli,

Erica Panicucci,

Giovanni Tripepi,

Ciro Tetta,

Roberto Palla

Publication year - 2008

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/gfm951

Subject(s) - medicine , renal replacement therapy , population , prospective cohort study , diabetes mellitus , proportional hazards model , surgery , endocrinology , environmental health

The 'RISchio CArdiovascolare nei pazienti afferenti all' Area Vasta In Dialisi' (RISCAVID) study is an observational and prospective trial including the whole chronic haemodialysis (HD) population in the northwest part of Tuscany (1.235 million people). The aim of the study was to elucidate the relevance of traditional and non-traditional risk factors of mortality and morbidity in HD patients as well as the impact of different HD modalities.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research